Nuvation Bio (NYSE:NUVB) Insider Kerry Wentworth Sells 36,750 Shares

Key Points

• Insider sale: Kerry Wentworth sold 36,750 shares on April 17 at an average of $5.01 for $184,117.50 under a pre-arranged Rule 10b5-1 plan, cutting her stake by 40.95% to 53,000 shares; she had also sold 200,000 shares on April 6 at $4.52.
• Stock and financials: Nuvation Bio traded at $5.13 (52‑week range $1.57–$9.75) with a $1.78B market cap, reporting in‑line quarterly EPS of ($0.11) and negative margins despite $41.87M in revenue.
• Market view and ownership: Analysts hold a "Moderate Buy" consensus with a $11.63 average target, while institutional investors own about 61.7% of the company and firms like Invesco have significantly increased their positions.

Nuvation Bio Inc. (NYSE:NUVB - Get Free Report) insider Kerry Wentworth sold 36,750 shares of the firm's stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $5.01, for a total value of $184,117.50. Following the completion of the transaction, the insider owned 53,000 shares of the company's stock, valued at approximately $265,530. This represents a 40.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kerry Wentworth also recently made the following trade(s):

• On Monday, April 6th, Kerry Wentworth sold 200,000 shares of Nuvation Bio stock. The stock was sold at an average price of $4.52, for a total value of $904,000.00.

Nuvation Bio Price Performance

NYSE NUVB traded up $0.01 during trading hours on Tuesday, hitting $5.13. The company had a trading volume of 3,584,527 shares, compared to its average volume of 4,944,549. Nuvation Bio Inc. has a 52 week low of $1.57 and a 52 week high of $9.75. The firm has a 50 day simple moving average of $4.87 and a 200 day simple moving average of $5.86. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.81 and a current ratio of 6.95. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -8.54 and a beta of 1.60.

Nuvation Bio (NYSE:NUVB - Get Free Report) last issued its earnings results on Monday, March 2nd. The company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11). Nuvation Bio had a negative return on equity of 57.48% and a negative net margin of 325.31%.The business had revenue of $41.87 million during the quarter, compared to the consensus estimate of $36.82 million. Equities research analysts expect that Nuvation Bio Inc. will post -0.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. HC Wainwright cut their target price on Nuvation Bio from $18.00 to $17.00 and set a "buy" rating for the company in a research note on Monday, January 12th. Royal Bank Of Canada lifted their price target on Nuvation Bio from $12.00 to $13.00 and gave the company an "outperform" rating in a research report on Tuesday, March 3rd. Truist Financial set a $13.00 price target on Nuvation Bio in a research report on Tuesday, January 27th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Nuvation Bio in a research report on Thursday, January 22nd. Finally, Wedbush reiterated an "outperform" rating and set a $11.00 price target on shares of Nuvation Bio in a research report on Thursday, April 16th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $11.63.

Institutional Trading of Nuvation Bio

A number of large investors have recently modified their holdings of NUVB. SG Americas Securities LLC increased its position in shares of Nuvation Bio by 41.4% during the 1st quarter. SG Americas Securities LLC now owns 87,387 shares of the company's stock valued at $375,000 after purchasing an additional 25,596 shares during the last quarter. Corient Private Wealth LLC bought a new stake in Nuvation Bio in the 4th quarter worth approximately $2,277,000. Invesco Ltd. lifted its position in Nuvation Bio by 138.2% in the 4th quarter. Invesco Ltd. now owns 1,185,143 shares of the company's stock worth $10,619,000 after buying an additional 687,597 shares during the last quarter. Beacon Pointe Advisors LLC lifted its position in Nuvation Bio by 60.4% in the 4th quarter. Beacon Pointe Advisors LLC now owns 259,212 shares of the company's stock worth $2,323,000 after buying an additional 97,612 shares during the last quarter. Finally, NewEdge Advisors LLC bought a new stake in Nuvation Bio in the 4th quarter worth approximately $8,531,000. Institutional investors own 61.67% of the company's stock.

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company's pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.